Information Provided By:
Fly News Breaks for March 5, 2020
Mar 5, 2020 | 06:23 EDT
BofA analyst Geoff Meacham downgraded Moderna to Neutral from Buy with an unchanged $32 price target. The analyst is keeping his positive view on the company's core pipeline and platform, but contends that its year-to-date stock price run-up of 40.5% is driven by its mRNA-1273 efforts on coronavirus, which he does not expect to be de-risked for some time.
News For MRNA From the Last 2 Days
May 19, 2022 | 09:55 EDT
Notable gainers among liquid option names this morning include Synopsys (SNPS) $292.33 +19.76, Live Nation (LYV) $90.59 +5.20, Moderna (MRNA) $143.87 +6.16, Expedia (EXPE) $124.71 +4.56, and Freeport McMoRan (FCX) $36.45 +1.11.